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Abstract 
Analgesics is a multibillion dollar worldwide industry. Oxycodone, an 
opioid, is currently administered using controlled release tablets; although this 
has resulted in considerable control over pain management, the controlled-
release tablets have been abused by drug users.  Measures to curb illicit use of 
the drug have not been successful, to date.  This study proposes that by 
incorporating the medicine into a micro- to nano-structurally optimized 
delivery material, release concentrations that cannot exceed therapeutic target 
levels will be achieved and therefore, curbing its misuse, even when the carrier 
material is crushed. Using Dextromethorphan (Dextro) as a model drug, silica 
xerogels (sol-gels) were synthesized by mixing tetramethoxysilane, Deionized 
water and HCl, in addition to Dextro-methanol solution.  Different drug loads 
and water-to-alkoxide ratios were observed to alter the micro- and nano-
structurural properties.   Different particle sizes were produced by crushing 
the xerogel discs, after which they were sieved and immersed in 5mg/ml PBS 
solution. Concentration of released Dextro was measured 
spectrophotometrically at 280 nm.  The effect of particle size on in vitro 
release of Dextro from xerogels, as a function of immersion time, 
demonstrated that both micro- to nano-sized particles exhibited time-
dependent release of Dextro. Although the release from nano-sized particles 
was noticeably faster than from the micro-sized ones, they did not show any 
burst release.  Data obtained demonstrate that synthesizing a delivery system 
capable of achieving the controlled-release of therapeutically relevant doses 
and misuse resistance are attainable.   
Keywords: Silica xerogel (sol-gel), Dextromethorphan (Dextro), 
microstructure, nanostructure, controlled-release, opioids, abuse  
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Introduction 
Analgesics represent hundreds of billions of dollars per year industry 
worldwide, and especially in the United States.  OxyContin was introduced in 
1996 and sales grew from $48 Million to $1.1 Billion in 2000 (Art, 2009).  The 
market consists of drugs used for the alleviation of pain due to injury, surgery, 
illness and chronic diseases. In previous years, morphine and many opioids 
derivatives have been widely used for the treatment of pain resulting from 
trauma, cancer or surgery. OxyContin is a semisynthetic opioid analgesic 
prescribed for acute, chronic or long-lasting pain.  It contains between 10-160 
mg of oxycodone HCl (active ingredient) in a time-release tablet (CSAT 
Advisory, 2001).  The sales of OxyContin in the United States generated $1.2 
billion in 2003 (Oxycontin, 2004); this rose up to $2.6 billion in 2012, 
although sales have declined in recent years, sales went down to $1.74 in 2017. 
In addition, opioids abuse has been linked to more than 42,000 overdose 
deaths in the United States in 2016, according to a report by the U.S. Centers 
for Disease Control and Prevention (Rudd et al, 2016).  Studies have proven 
OxyContin to be effective in the treatment of various types of pain. It is most 
often prescribed for pain associated with arthritis, lower back conditions, 
injuries, and cancer. In 1996, controlled-release OxyContin became available 
in 12-hour time release tablets in doses ranging from 10 mg to 160 mg per 
tablet (Oxycontin, 2004). The higher doses of 80 mg and 160 mg are 
administered to opioid (narcotic) tolerant individuals.  Unlike other analgesics, 
like aspirin or acetaminophen, with threshold to their effectiveness, 
OxyContin can potentially provide up to four times the relief of a non-opioid 
analgesic, such that the most severe degree of pain can be managed (Kaplan 
et al, 1998; Hale et al, 1999; Staumbaugh et al, 2001; Art, 2009). The 
development of these controlled-release tablets was a marked improvement 
over the conventional tablets that only lasted for 3 to 4 hours and required 
patients to swallow more tablets each day in order to control their intense pain. 
Although controlled-release tablets have enabled patients to gain 
considerable control over their pain, OxyContin has become a significant 
source of drug abuse. It has been documented that emergency rooms in the US 
treated an estimated 5,261 people from January to June 2000 for abuse of 
OxyContin (Pleurvy, 2004, CBHSQ, 2016) and these figures have risen 
astronomically since.  In 2015 alone, drug overdose was reported to be the 
leading cause of accidental death in the US, with 52,404 lethal drug overdoses. 
Opioid addiction has been identified to be driving this epidemic, with 20,101 
overdose deaths related to prescription pain relievers, and 12,990 overdose 
deaths related to heroin (Rudd et al, 2016)   It is estimated that 20.5 million 
people in the United States are dependent on or abuse opioid painkillers and 
that 23% of the population develop opioid addiction (NIDA, 2014). Drug 
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overdose is the leading cause of accidental death in the US and opioid 
addiction is driving this epidermic (NIDA, 2014; Rudd et al, 2016).  
OxyContin is abused by crushing or dissolving the tablets and 
swallowing, snorting or injecting the drug contents released. When abused, 
OxyContin can be dangerously addictive.  In addition to addiction due to drug 
abuse, psychological well-being of individuals can be inhibited as well 
(Olufunke, 2017). Measures taken by manufacturers and traditional 
pharmaceutical companies to curb the illicit use of the drug have not been 
successful yet.  Thus, there is a considerable interest in the development of 
alternative controlled release methods (Kota et al, 2005; Wang et al, 2009, 
Tahereh et al, 2013; Purdue Pharma, 2019) that are abuse-proof.  This study 
proposes that by incorporating the medicine in a nanostructurally optimized 
delivery material, release concentrations will be achieved that cannot exceed 
therapeutic target levels even when the carrier material is crushed. This 
preliminary data represents an outstanding basis for achieving controlled-
release of Oxycontin for pain relief over a long period of time, as well as, 
inhibiting its use for recreation.  
Using silica precursors such as tetramethoxysilane (TMOS) or 
tetraethoxysilane (TEOS), silica sol gels can be synthesized via hydrolysis and 
condensation reactions (Kota et al, 2005, Yoshio et al, 2005, Beibei et al, 
2011). The hydrolysis reaction, which could be either acid or base catalyzed, 
could replace alkoxide groups with hydroxyl groups. Siloxane bonds (Si-O-
Si) may be formed during subsequent condensation. Alcohol and water which 
are byproducts of the condensation reaction evaporate while drying. The step 
by step chemical reactions within the process starts with the Stӧber Process 
(Radin and Ducheyne, 2004; Tian-Song et al, 2009, Li and Jianjun, 2013) 
hydrolysis, and ends with condensation.  
Theoretically, the chemical reactions that occur in the process are 
modelled according to the Stӧber Process (Stӧber, 1968; Wang et al, 2009; 
Tahereh et al, 2013) which involved hydrolysis and condensation.  The overall 
reaction may be summed up as: 
nSi(OR)4 + 2nH2O  nSiO2 + 4nROH 
However, the completion of the reaction and the chemical composition 
of the resulting products depend on the excess of water above the 
stoichiometric H2O/Si ratio of 2. Many other sol-gel processing parameters 
(such as pH of the sol, type and concentration of solvents, temperature, aging 
and drying schedules) can also affect the composition, structure, and 
properties of the resulting products (Kota et al, 2005, Yoshio et al, 2005, 
Beibei et al, 2011).  
Drug molecules are then incorporated into the nano-sized pore 
channels of the micro-to-nano-sized particles and are released by diffusion 
through the aqueous phase that penetrates these pores. In our laboratory, we 
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have developed a deep understanding regarding nano-structural control of the 
release properties of sol-gels (Oxycontin, 2004; Rudd et al, 2016). The 
variation of processing parameters leads to variations of pore sizes and 
porosity, which in turn affect the release rates of the drug molecules (Tian-
Song et al, 2009; Li and Jianjun, 2013).  These findings were summarized in 
a review paper titled “Nanostructural control of implantable xerogels for the 
controlled release of biomolecules” (Falaize et al, 1999; Radin and Ducheyne, 
2004). 
 The goals of this research were (i) to develop a sol-gel system for the 
release of an opioid compound with the potential to provide sustained relief 
from post-operative pain over a period of time (from one to several weeks); 
(ii) formulate a drug carrying system that will be impervious to recreational 
use/abuse, either by crushing, or by dissolving in solution to obtain a burst 
release of the active ingredients.   By using a model opioid such as 
dextromethorphan, it is possible to determine the feasibility of loading high 
concentrations (up to 80 mg/g) of the drug into the xerogels; demonstrate the 
principle of preventing abuse of drug by determining the effects of drug load 
(high versus low) and particle size (fine versus large) on the release profile of 
dextromethorphan from silica xerogels. 
 
Materials and Methods:  
In this first series of experiments, we used a model molecule, 
Dextromethorphan, which is an inactive opioid. The experimental design was 
based on the assumptions that: the use of low water/alkoxide ratio would 
enable the prevention of  burst release from finely crushed particles (the water-
to-alkoxide ratio is a parameter associated with the synthesis of the 
nanostructure sol-gel controlled release carriers); since solubility of 
dextromethorphan is low in water (15 mg/ml) and high in alcohols (up to 200 
mg/ml in methanol), the use of alcohol solutions for the synthesis of drug-
loaded xerogels would result in obtaining higher loads (up to 80 mg/g) of this 
drug.  
Table 1 shows comparison between the characteristic properties of 
Oxycontin and the model opioid, Dextromethorphan, used in the study.  Silica 
xerogels with water/alkoxide ratio of 4 and nominal dextromethorphan 
concentrations (W, %) of either 20 mg/g or 80 mg/g, were synthesized by 
using acid-catalyzed hydrolysis of Tetramethyl Orthosilicate (TMOS-98%, 
Aldrich). After mixing TMOS, DI water and 1N HCl a sol was formed and 
corresponding amounts of Dextromethorphan - Methanol solution were added.  
The sols were cast into polystyrene vials (1 ml in each vial), sealed, 
allowed to gel and age for 3 days. The vials were unsealed, and the gels were 
dried at room temperature till constant weights were attained. Weight loss for 
both 20mg/g and 80 mg/g gels was about 70%. The resulting xerogel disks 
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were crushed and particles of three different size ranges, 200-500 m, 40-70 
m, and 20-40 m, were produced by sieving, although the smallest micro- 
to nano-sizes were exceedingly difficult to produce.  The various stages in the 
chemical processes including hydrolysis and condensation are outlined below:  
 
Chemical Reactions: 
Hydrolysis:  Si-OR  +  H2O                    Si-OH  +  ROH
Alcohol:  Si-OH  +  RO-Si                 Si-O-Si  +  ROH
Water Condensation:  Si-OH  +  HO-Si                 Si-O-Si  +  H2O
Overall Reaction:  nSi(OR)4  +  2nH2O                 nSiO2  +  4nROH 
 
 Stӧber Process (Stӧber, 1968; Wang et al, 2009; Tahereh et al, 2013) 
 
Hydrolysis:
Si(OR)4  +  4H2O                       Si(OH)4  +  4ROH
Si(OH)4                         SiO2  +  2H2O
R = Alkyl, preferred C2H5
NH3
ROH
 
NB:  Using TEOS alkoxide and ammonia catalyst, spherical nanoparticles with well-
defined sizes were produced. 
 
The drug release procedure was carried out in phosphate buffered saline 
solution (PBS) environment at pH of 7.4 and at a physiological temperature of 37 
°C. The setup was placed on a continual vibrating and rotating platform at 100 
rpm.  
The particles which were obtained as a result of the crushed xerogels were 
immersed in PBS at a ratio between weight and solution volume of 5 mg/ml.  
Meanwhile, the solutions in which the particles were immersed were exchanged 
daily.  The concentration of released dextromethorphan (into the surrounding 
PBS solution) was measured spectrophotometrically at 280 nm. 
 
Results: 
Figure 1 shows a schematic and spatial orientation of the Dextro 
molecule indicating the positions of the Oxygen and Nitrogen in the molecule, 
showing the spatial orientation of Carbon, Nitrogen and Hydrogen atoms.  The 
Nitrogen atom is very prominent in the structure (Falaize et al, 1999) and the 
chemical formula of Dextro: C18H28BrNO2 (Table 1). 
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In vitro release of dextromethorphan as a function of immersion time, 
for 20mg/g and 80 mg/g, xerogels is shown in Figures 2 and 3 respectively.  
The figures show the mean cumulative release of Dextromethorphan from 20 
mg/g-xerogels (Fig. 2) and from 80 mg/g-xerogels (Fig. 3) as a function of 
immersion time in PBS. The percentage release at various time points is also 
indicated (n = 3, error bars represent standard deviation – by their small sizes). 
The data demonstrates that both large (200-500 m) and fine (20-40 and 40-
70 m) particles showed time-dependent and load-dependent release of 
Dextro. Although the release from smaller micro- to nano-sized particles was 
noticeably faster than from larger ones, the smaller particles did not show any 
burst release. Specifically, after one day of immersing particles in PBS, only 
2% to 4% of the original load were released from the micro- to nano- sized 
particles obtained from the 20mg/g- and 80 mg/g-xerogels, respectively.  
The controlled burst release continued throughout the period in which particles 
were immersed in PBS. Over the seven days duration, only 17% of the original 
drug load was released from the micro- to nano-sized particles obtained from 
both the 20 mg/g- and 80 mg/g-xerogels. 
 
Table 1: Table shows a comparison between the characteristic properties of Oxycontin and 
the model opioid, Dextromethorphan Hydrobrmide (NCBI, 2019a; NCBI, 2019b) 
Property  OxyContin Dextromerthophan HBr 
1. Molecular weight  351.83 370.331 
2. Chemical Formula  C18H21NO4.HCl C18H28BrNO2 
3. Physical properties:  White, odorless, crystalline White, odorless, crystalline 
 4. Solubility 
      a) In water 
      b) In alcohol 
      
 16g/100mL 
Slightly soluble in alcohol 
1.5g/100mL 
Soluble 1 in 10 of ethanol 
(10g/100mL) 
Freely soluble in chloroform 
5. pH   Of 1 % aqueous solution is 5.2 – 6.5 
6. Chemical name  4, 5-epoxy-14-hydroxyl-3-methyl-
17-methylmorphinan-6-one 
hydrochloride 
3 methoxy-17-methylmorphinan 
monohydrate 
7. Type  Opioid analgesic (oxycodone is pure 
agonist opioid) 
Synthetic compound; d-isomer of 
levophenol, a codein analogue and 
opioid analgesic 
8. Drug name  Oxycodone hydrochloride Dextromethorphan hydrobromide 
Dextromethorphan hydrobromium 
Demorphan hydrobromide 
9. Trade name  OxyContin Polistirex Exended Release 
Suspension 
10. Therapeutic dosages              10, 20, 40 80 & 160 mg 10, 20, 30 and 60 mg 
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Figure 1. A-2D schematic of the Molecular structure of Dextromethorphan Hydrobromide 
(Dextro), with formula C18H28BrNO2, similar to OxyContin. (NCBI, 2019c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mean cumulative release of Dextromethorphan from 20 mg/g-xerogels. 
Figure 3. Mean cumulative release of Dextromethorphan from 80 mg/g-xerogels. 
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Discussion and Conclusion: 
The formulation of the research question was based on the premise that 
a novel sol-gel controlled-release technology will offer a fundamental solution 
to the issue of abuse associated with controlled-release opioids. The data 
obtained in this study, so far, demonstrates that a delivery material can be 
synthesized to achieve controlled release of therapeutically relevant doses. 
The experiment was carried out over a seven-day period, for a start.  The 
researcher intends to extend the duration of the experiments for longer periods 
in order to further monitor the controlled-release mechanism of opioids. 
The data obtained so far, affirms that the principle of misuse resistance 
can be accomplished, since no burst release associated with the controlled-
release sol-gel materials (Santos et al, 1999; Radin et al, 2001; Cicero et al, 
2012), was observed. These finding were valid and independent of the size of 
the controlled release particles. It is obvious, therefore, that it may not be 
feasible to dissolve the drug and obtain large quantities sufficient for 
recreational use in any reasonable time frame. In addition, the controlled-
release carrier cannot be cast into much smaller particle sizes, less than the 
micro-to nano-sized particle sizes obtained, which may be useful for injection 
(abuse).  That is, reducing the particle sizes, further, to ranges below what was 
realized, in this study, may be very challenging, unrealistic and may not lead 
to any significant increase in the release or burst effect.  Therefore, any attempt 
to formulate the products to obtain below the nano-sized formulations, may be 
highly impracticable and may only lead to strengthening the misuse resistance 
concept. 
In 2009, an abuse-deterrent formulation of the prescription opioid 
OxyContin was introduced with the intention of making OxyContin more 
difficult to solubilize or crushed, thereby discouraging its abuse through 
injection and inhalation.   Subsequently, a study was done (between 2009 and 
2012) to examine the effect of the abuse-deterrent formulation on its use in 
relation to other opioids (Ciero et al, 2012).  The study showed that users 
unanimously preferred older versions of drugs since those were more prone to 
abuse.  There was, however, no evidence to support the assertion that abusers 
of OxyContin terminated their drug misuse because of the abuse-deterrent 
formulation. Instead, it appeared that they simply switched their attention to 
alternative drug choices.  The data, nevertheless, shows that an abuse-deterrent 
formulation can successfully reduce abuse of an opioid to a very large extent.  
However, an unanticipated outcome that may be generated, which is, replacing 
the abuse-deterrent formulation with an alternative opioid medication may 
pose a greater overall risk to public health than OxyContin.   The study 
therefore concluded that abuse-deterrent formulations is not the “magic bullet” 
that may hopefully solve the growing problem of opioid abuse (Ciero et al, 
2012).  In view of this and many other findings, it is imperative that an 
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alternative and viable solutions are sought to address the abuse problem. The 
solution lies, therefore, in engineering an abuse-free drug carrier to alleviate 
the problem, which this study addresses. 
The objective of this study was to control opioid release, independent 
of the size of the pellet or powder particles in which the drug was incorporated. 
This was achieved by encasing the active substance in pore spaces within the 
fabricated sol-gels, such that they could not be breached mechanically since 
this class of controlled-release materials were made as monoliths 
(Aughenbaugh et al, 2002, Radin et al, 2004, Taylor et al, 2016) and could not 
be crushed to smaller particle sizes. These sol-gel particle sizes are three orders 
of magnitude larger than the pore channels (about 2 nm) that were created to 
contain the opioid. Consequently, the data obtained in this study, therefore, is 
proof of the principle that synthesizing a micro- to nano-sized dimensional 
drug delivery carrier that may be highly resistant to misuse and abuse is 
feasible and achievable. 
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